Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for NRIX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
May 31, 2026 -96.57M
February 28, 2026 -71.91M
November 30, 2025 -67.83M
August 31, 2025 -57.38M
May 31, 2025 -63.16M
February 28, 2025 -61.09M
November 30, 2024 -48.75M
August 31, 2024 -42.18M
May 31, 2024 -39.70M
February 29, 2024 -41.95M
November 30, 2023 26.69M
August 31, 2023 -41.13M
May 31, 2023 -18.47M
February 28, 2023 -48.45M
November 30, 2022 -37.96M
Date Value
August 31, 2022 -46.31M
May 31, 2022 -32.91M
February 28, 2022 -42.63M
November 30, 2021 -30.91M
August 31, 2021 -29.97M
May 31, 2021 -31.54M
February 28, 2021 8.053M
November 30, 2020 -20.48M
August 31, 2020 -6.141M
May 31, 2020 -14.43M
February 29, 2020 40.97M
November 30, 2019 -12.75M
August 31, 2019 36.37M
May 31, 2019 -13.34M
February 28, 2019 -9.682M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Monte Rosa Therapeutics, Inc. -44.11M
Gilead Sciences, Inc. 3.573B
TG Therapeutics, Inc. 39.26M
Cue Biopharma, Inc. -29.00M
Keros Therapeutics, Inc. -20.42M